Danaher stock: 3 ways Masimo deal could boost stock

Masimo (NASDAQ: MASI) pushed meaningfully higher on Feb. 17 after healthcare giant Danaher (NYSE: DHR) said it will acquire the pulse oximetry leader for $180 a share in cash. Valued at about $9.9 billion, this agreement will see Masimo go private and become a “standalone” unit within Danaher’s diagnostics segment. While MASI shareholders are enjoying an immediate payday, the real story for long-term investors lies in Danaher stock that remains down some 15% versus its year-to-date high. By swallowing a high-growth medical innovator, DHR is positioning itself for a massive re-rating as it integrates Masimo’s “sticky” hospital technology into its legendary operational engine. Why Masimo acquisition is bullish for Danaher stock Investors cheered Masimo news on Tuesday mostly because the…